Results of the surveillance of tedizolid activity and resistance program: In vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe

Diagnostic Microbiology and Infectious Disease

Volumn 81, Issue 2, 2015, Pages 112-118

  Sahm, Daniel F ^a   Deane, Jennifer ^a   Bien, Paul A ^b   Locke, Jeffrey B ^b   Zuill, Douglas E ^b   Shaw, Karen J ^b   Bartizal, Ken F ^b  

^a Eurofins Medinet Inc   (Germany)

^b Trius Therapeutics   (United States)

Author keywords

Cfr; Linezolid; Oxazolidinone; Surveillance; Tedizolid

Indexed keywords

LINEZOLID; RIBOSOMAL PROTEIN L3; RIBOSOMAL PROTEIN L4; RIBOSOME PROTEIN; RNA 23S; TEDIZOLID; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CFR GENE; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; EUROPE; GENE; GENE MUTATION; GRAM POSITIVE BACTERIUM; HEMOLYTIC STREPTOCOCCUS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; UNITED STATES; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; GENETICS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; EPIDEMIOLOGICAL MONITORING; EUROPE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; UNITED STATES;

EID: 84922309807     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.08.011     Document Type: Article

References (38)

1. Besier S., Ludwig A., Zander J., Brade V., Wichelhaus T.A. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother 2008, 52:1570-1572.
2. Bourgeois-Nicolaos N., Massias L., Couson B., Butel M.J., Andremont A., Doucet-Populaire F. Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo. J Infect Dis 2007, 195(10):1480-1488.
3. Brown S.D., Traczewski M.M. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010, 54:2063-2069.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement, in CLSI document M100-S22 2012, CLSI, Wayne, PA.
5. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition, in CLSI document M7-A9 2012, CLSI, Wayne, PA.
6. Flamm R.K., Farrell D.J., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centers in 24 countries. J Chemother 2012, 24:328-337.
7. Flamm R.K., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother 2013, 57:1077-1081.
8. Im W.B., Choi S.H., Park J.Y., Choi S.H., Finn J., Yoon S.H. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem 2011, 46(4):1027-1039.
9. Jones R.N., Ross J.E., Fritsche T.R., Sader H.S. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program assessing isolates from 16 nations. J Antimicrob Chemother 2006, 57:279-287.
10. Kaminska K.H., Purta E., Hansen L.H., Bujnicki J.M., Vester B., Long K.S. Insights into the structure, function and evolution of the radical-SAM 23S rRNA methyltransferase Cfr that confers antibiotic resistance in bacteria. Nucleic Acids Res 2010, 38:1652-1663.
11. Kosowska-Shick K., Julian K.G., McGhee P.L., Appelbaum P.C., Whitener C.J. Molecular and epidemiologic characteristics of linezolid-resistant coagulase-negative staphylococci at a tertiary care hospital. Diagn Microbiol Infect Dis 2010, 68:34-39.
12. Liu Y., Wang Y., Schwarz S., Wang S., Chen L., Wu C., et al. Investigation of a multiresistance gene cfr that fails to mediate resistance to phenicols and oxazolidinones in Enterococcus faecalis. J Antimicrob Chemother 2014, 69:892-898.
13. Locke J.B., Hilgers M., Shaw K.J. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009, 53:5265-5274.
14. Locke J.B., Hilgers M., Shaw K.J. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother 2009, 53:5275-5278.
15. Locke J.B., Finn J., Hilgers M., Morales G., Rahawi S., G C K., et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010, 54:5337-5343.
16. Locke J.B., Rahawi S., Lamarre J., Mankin A.S., Shaw K.J. Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05. Antimicrob Agents Chemother 2012, 53:5265-5274.
17. Long K.S., Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 2012, 56:603-612.
18. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., Vester B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006, 50:2500-2505.
19. Marshall S.H., Donskey C.J., Hutton-Thomas R., Salata R.A., Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002, 46:3334-3336.
20. Meka V.G., Pillai S.K., Sakoulas G., Wennersten C., Venkataraman L., DeGirolami P.C., et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004, 190:311-317.
21. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008, 52:2244-2246.
22. Mendes R.E., Deshpande L.M., Farrell D.J., Spanu T., Fadda G., Jones R.N. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 2010, 65:2329-2335.
23. Mendes R.E., Flamm R.K., Hogan P.A., Ross J.E., Jones R.N. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrob Agents Chemother 2014, 58:1243-1247.
24. Mendes R.E., Hogan P.A., Streit J.M., Jones R.N., Flamm R.K. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12). J Antimicrob Chemother 2014, 69(6):1582-1588.
25. Moran G.J., Fang E., Corey G.R., Das A.F., De Anda C., Prokocimer P. Once-daily tedizolid for 6 days versus twice-daily linezolid for 10 days in acute bacterial skin and skin structure infections: results from a randomised controlled trial using an intravenous-to-oral switch strategy (ESTABLISH-2 study). Lancet Infect Dis 2014, 14(8):696-705.
26. Muñoz K.A., Bien P., Bethune C., Wright R., Prokocimer P. Absolute bioavailability and intravenous pharmacokinetics of torezolid phosphate in healthy subjects. Poster presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria. April 10-13, 2013. Abstract 813 2013.
27. Pillai S.K., Sakoulas G., Wennersten C., Eliopoulos G.M., Moellering R.C., Ferraro M.J., et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis 2002, 186:1603-1607.
28. Prokocimer P., Bien P., Surber J., Mehra P., DeAnda C., Bulitta J.B., et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011, 55:583-592.
29. Prokocimer P., Bien P., DeAnda C., Pillar C.M., Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012, 56:4608-4613.
30. Prokocimer P., De Anda C., Fang E., Mehra P., Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013, 309:559-569.
31. Prystowsky J., Siddiqui F., Chosay J., Shinabarger D.L., Millichap J., Peterson L.R., et al. Resistance to linezolid: character of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001, 45:2154-2156.
32. Schaadt R., Sweeney D., Shinabarger D., Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009, 53:3236-3239.
33. Shaw K.J., Poppe S., Schaadt R., Brown-Driver V., Finn J., Pillar C.M., et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008, 52:4442-4447.
34. Smith L.K., Mankin A.S. Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. Antimicrob Agents Chemother 2008, 52:1703-1712.
35. Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007, 64:1506-1514.
36. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208.
37. Wolter N., Smith A.M., Farrell D.J., Schaffner W., Moore M., Whitney C.G., et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 2005, 49:3554-3557.
38. Wong A., Reddy S.P., Smyth D.S., Aguero-Rosenfeld M.E., Sakoulas G., Robinson D.A. Polyphyletic emergence of linezolid-resistant staphylococci in the United States. Antimicrob Agents Chemother 2010, 54:742-748.